曾力楠;张伶俐;
ZENG Li'nan;ZHANG Lingli;Department of Pharmacy,West China Second University Hospital,Sichuan University;Evidence-Based Pharmacy Center,West China Second University Hospital,Sichuan University;Key Laboratory of Birth Defects and Related Diseases of Women and Children,Sichuan University,Ministry of Education;MAGIC;

• 1:四川大学华西第二医院药学部
• 2:四川大学华西第二医院循证药学中心
• 3:出生缺陷与相关妇儿疾病教育部重点实验室
• 4:MAGIC

摘要(Abstract)：

随着新型冠状病毒肺炎在全球暴发及快速传播,大量相关研究证据迅速产生。然而,因证据质量参差不齐、证据转化质量不佳、证据转化速度较慢等问题,卫生决策者、临床医生及患者如何作出正确决策面临巨大挑战。基于快速系统评价证据,快速建议指南可及时、有效地将当前最新证据转化为指导临床实践的推荐意见。面对全球突发公共卫生事件,通过构建新型证据生态系统,形成证据从生产、评价到应用、转化的完整闭环,从而提高医疗实践水平、减少卫生资源浪费。
With the outbreak and rapid spread of the COVID-19 worldwide, a large amount of relevant research evidence has quickly emerged. However, due to the uneven quality of evidence, poor quality and slow speed of evidence translation, it is a big challenge for health decision-makers, clinicians, and patients to make evidence-based decisions. Based on rapid systematic review of evidence, the rapid advice-guidelines can promptly and effectively transform the latest current evidence into recommendations guiding clinical practice. In the face of global public health emergencies, by building a new type of evidence ecosystem, a completely closed loop of evidence from production and evaluation to application and transformation is formed to improve the level of medical practice and reduce the waste of health resources.

关键词(KeyWords)： 新型冠状病毒肺炎;快速建议指南;循证决策
coronavirus disease 2019;rapid advice guidelines;evidence-based decision

Abstract:

Keywords:

基金项目(Foundation): 四川省科技计划项目(重点研发项目)(2020YFS0035);四川省科技计划项目(重点研发项目)子课题(20ZDYF3101)~~

作者(Authors): 曾力楠;张伶俐;
ZENG Li'nan;ZHANG Lingli;Department of Pharmacy,West China Second University Hospital,Sichuan University;Evidence-Based Pharmacy Center,West China Second University Hospital,Sichuan University;Key Laboratory of Birth Defects and Related Diseases of Women and Children,Sichuan University,Ministry of Education;MAGIC;

参考文献(References)：

• [1] World Health Organization.WHO Coronavirus Disease (COVID- 19) Dashboard[EB/OL].(2020- 12- 09)[2020- 12- 09].https://covid19.who.int/.
• [2] Centers for Disease Control and Prevention.Coronavirus (COVID- 19)[EB/OL].(2020- 12- 08)[2020- 12- 09].https://www.cdc.gov/coronavirus/2019-ncov/index.html.
• [3] European Centre for Disease Prevention and Control.COVID- 19 pandemic[EB/OL].(2020- 12- 08)[2020- 12- 09].https://www.ecdc.europa.eu/en/COVID- 19-pandemic.
• [4] Chalmers I,Glasziou P.Avoidable waste in the production and reporting of research evidence[J].Lancet,2009,374:86- 89.
• [5] Glasziou PP,Sanders S,Hoffmann T.Waste in COVID- 19 research[J].BMJ,2020,369:m1847.
• [6] Budhathoki P,Shrestha DB,Rawal E,et al.Corticosteroids in COVID- 19:Is it Rational?A Systematic Review and Meta-Analysis[J].SN Compr Clin Med,2020,19:1- 21.
• [7] Cano EJ,Fonseca Fuentes X,Corsini Campioli C,et al.Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes:Systematic Review and Meta-analysis[J].Chest,2021,159:1019- 1040.
• [8] Cheng WW,Li YF,Cui LY,et al.Efficacy and Safety of Corticosteroid Treatment in Patients With COVID- 19:A Systematic Review and Meta-Analysis[J].Front Pharmacol,2020,11:571156.
• [9] Halpin DMG,Singh D,Hadfield RM.Inhaled corticos-teroids and COVID- 19:a systematic review and clinical perspective[J].Eur Respir J,2020,55:2001009.
• [10] Lee KH,Yoon S,Jeong GH,et al.Efficacy of Corticosteroids in Patients with SARS,MERS and COVID- 19:A Systematic Review and Meta-Analysis[J].J Clin Med,2020,9:2392.
• [11] Li H,Chen CX,Hu F,et al.Impact of corticosteroid therapy on outcomes of persons with SARS-CoV- 2,SARS-CoV,or MERS-CoV infection:a systematic review and meta-analysis[J].Leukemia,2020,34:1503- 1511.
• [12] Shuto H,Komiya K,Yamasue M,et al.A systematic review of corticosteroid treatment for noncritically ill patients with COVID- 19[J].Sci Rep,2020,10:20935.
• [13] Singh AK,Majumdar S,Singh R,et al.Role of corticosteroid in the management of COVID- 19:A systemic review and a Clinician’s perspective[J].Diabetes Metab Syndr,2020,14:971- 978.
• [14] Sterne JAC,Diaz J,Villar J,et al.Corticosteroid therapy for critically ill patients with COVID- 19:A structured summary of a study protocol for a prospective meta-analysis of randomized trials[J].Trials,2020,21:734.
• [15] Tlayjeh H,Mhish OH,Enani MA,et al.Association of corticosteroids use and outcomes in COVID- 19 patients:A systematic review and meta-analysis[J].J Infect Public Health,2020,13:1652- 1663.
• [16] Veronese N,Demurtas J,Yang L,et al.Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia:A Systematic Review of the Literature[J].Front Med (Lausanne),2020,7:170.
• [17] Yang ZW,Liu JL,Zhou YJ,et al.The effect of corticosteroid treatment on patients with coronavirus infection:a systematic review and meta-analysis[J].J Infect,2020,81:e13- e20.
• [18] Ye Z,Wang Y,Colunga-Lozano LE,et al.Efficacy and safety of corticosteroids in COVID- 19 based on evidence for COVID- 19,other coronavirus infections,influenza,community-acquired pneumonia and acute respiratory distress syndrome:a systematic review and meta-analysis[J].CMAJ,2020,192:E756-E767.
• [19] Sharma SK,Mishra M,Mudgal SK.Efficacy of cloth face mask in prevention of novel coronavirus infection transmis-sion:A systematic review and meta-analysis[J].J Educ Health Promot,2020,9:192.
• [20] Long Y,Hu T,Liu L,et al.Effectiveness of N95 respirators versus surgical masks against influenza:A systematic review and meta-analysis[J].J Evid Based Med,2020,13:93- 101.
• [21] Liang M,Gao L,Cheng C,et al.Efficacy of face mask in preventing respiratory virus transmission:A systematic review and meta-analysis[J].Travel Med Infect Dis,2020,36:101751.
• [22] Jefferson T,Del Mar CB,Dooley L,et al.Physical interventions to interrupt or reduce the spread of respiratory viruses[J].Cochrane Database Syst Rev,2020(11):CD006207.
• [23] Chu DK,Akl EA,Duda S,et al.Physical distancing,face masks,and eye protection to prevent person-to-person transmission of SARS-CoV- 2 and COVID- 19:a systematic review and meta-analysis[J].Lancet,2020,395:1973- 1987.
• [24] Camargo MC,Martinez-Silveira MS,Lima AA,et al.Effectiveness of the use of non-woven face mask to prevent coronavirus infections in the general population:a rapid systematic review[J].Cien Saude Colet,2020,25:3365- 3376.
• [25] Brainard J,Jones NR,Lake IR,et al.Community use of face masks and similar barriers to prevent respiratory illness such as COVID- 19:a rapid scoping review[J].Euro Surveill,2020,25:2000725.
• [26] Aggarwal N,Dwarakanathan V,Gautam N,et al.Facemasks for prevention of viral respiratory infections in community settings:A systematic review and meta-analysis[J].Indian J Public Health,2020,64:S192-S200.
• [27] Casigliani V,De Nard F,De Vita E,et al.Too much information,too little evidence:is waste in research fuelling the COVID- 19 infodemic?[J].BMJ,2020,370:m2672.
• [28] Landhuis E.Scientific literature:Information overload[J].Nature,2016,535:457- 458.
• [29] Sampson M,Shojania KG,Garritty C,et al.Systematic reviews can be produced and published faster[J].J Clin Epidemiol,2008,61:531- 536.
• [30] Elliott JH,Turner T,Clavisi O,et al.Living systematic reviews:an emerging opportunity to narrow the evidence-practice gap[J].PLoS Med,2014,11:e1001603.
• [31] Jadad AR,Cook DJ,Jones A,et al.Methodology and reports of systematic reviews and meta-analyses:a comparison of Cochrane reviews with articles published in paper-based journals[J].JAMA,1998,280:278- 280.
• [32] Shojania KG,Sampson M,Ansari MT,et al.How quickly do systematic reviews go out of date?A survival analysis[J].Ann Intern Med,2007,147:224- 233.
• [33] 靳英辉，蔡林，程真顺，等.新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版)[J].解放军医学杂志，2020,45:1- 20.Jin YH,Cai L,Cheng ZS,et al.A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)[J].Jiefangjun Yixue Zazhi,2020,45:1- 20.
• [34] Dagens A,Sigfrid L,Cai E,et al.Scope,quality,and inclusivity of clinical guidelines produced early in the COVID- 19 pandemic:rapid review[J].BMJ,2020,369:m1936.
• [35] Brouwers MC,Kerkvliet K,Spithoff K,et al.The AGREE Reporting Checklist:a tool to improve reporting of clinical practice guidelines[J].BMJ,2016,352:i1152.
• [36] World Health Organization.WHO handbook for guideline development.2nd edition[M/OL].[2020- 12- 09].https://apps.who.int/iris/handle/10665/145714.
• [37] Garritty CM,Norris SL,Moher D.Developing WHO rapid advice guidelines in the setting of a public health emergency[J].J Clin Epidemiol,2017,82:47- 60.
• [38] World Health Organization.Rapid risk assessment of acute public health events[EB/OL].[2020- 12- 09].https://www.who.int/csr/resources/publications/HSE_GAR_ARO_2012_1/en/.
• [39] World Health Organization.Emergency Response Framework (ERF)[EB/OL].[2020-12-09].https://www.who.int/hac/about/erf/en/.
• [40] Kowalski SC,Morgan RL,Falavigna M,et al.Develop-ment of rapid guidelines:1.Systematic survey of current practices and methods[J].Health Res Policy Syst,2018,16:61.
• [41] The BMJ.BMJ Rapid Recommendations[EB/OL].(2020- 12- 17)[2020- 12- 30].https://www.bmj.com/rapid-recommendations.
• [42] Rochwerg B,Agarwal A,Zeng L,et al.Remdesivir for severe COVID- 19:a clinical practice guideline[EB/OL].(2020-07-30)[2020-12-30].https://www.bmj.com/content/370/bmj.m2924.
• [43] National Institutes of Health.COVID- 19 treatment guidelines[EB/OL].(2020-11-27)[2020-12-30].https://www.covid19treatmentguidelines.nih.gov/whats-new/.
• [44] Up to Date.Coronavirus disease 2019 (COVID- 19):management in hospitalized adults[EB/OL].(2020-11-27)[2020- 12- 30].https://www.uptodate.com/contents/coronavirus- disease- 2019-COVID- 19-management-in-hospitalized-adults.
• [45] Beigel JH,Tomashek KM,Dodd LE,et al.Remdesivir for the treatment of COVID- 19-Final Report[J].N Engl J Med,2020,383:1813- 1826.
• [46] Lamontagne F,Agoritsas T,Macdonald H,et al.A living WHO guideline on drugs for COVID- 19[EB/OL].(2020- 09- 04)[2021- 02- 02].https://www.bmj.com/content/370/bmj.m3379.
• [47] World Health Organization.Corticosteroids for COVID- 19:living guidance[EB/OL].(2020- 09- 02)[2021- 02- 02].https://apps.who.int/iris/handle/10665/334125.
• [48] Graham R,Mancher M,Wolman DM,et al.Clinical practice guidelines we can trust[M].Washington DC:the National Academies Press,2011.
• [49] Elliott JH,Synnot A,Turner T,et al.Living systematic review:1.Introduction-the why,what,when,and how[J].J Clin Epidemiol,2017,91:23- 30.
• [50] Thomas J,Noel-Storr A,Marshall I,et al.Living systematic reviews:2.Combining human and machine effort[J].J Clin Epidemiol,2017,91:31- 37.
• [51] Simmonds M,Salanti G,McKenzie J,et al.Living Systematic Review Network.Living systematic reviews:3.Statistical methods for updating meta-analyses[J].J Clin Epidemiol,2017,91:38-46.
• [52] Akl EA,Meerpohl JJ,Elliott J,et al.Living Systematic Review Network.Living systematic reviews:4.Living guideline recommendations[J].J Clin Epidemiol,2017,91:47- 53.
• [53] 许吉，邓宏勇.动态系统评价简介[J].中国循证医学杂志，2020,20:244- 248.Xu J,Deng HY.A brief introduction of living systematic review[J].Zhongguo Xunzheng Yixue Zazhi,2020,20:244- 248.
• [54] 张迁，王琪，后亮瑛，等.动态指南制订方法及案例介绍[J].中国循证医学杂志，2021,21:491- 496.
• [55] MAGIC.Our approach[EB/OL].(2020- 12- 11)[2020- 12- 11].https://magicevidence.org/approach/.